Astrana Health, Inc. (NASDAQ:ASTH) Receives $65.60 Average Price Target from Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $56.83.

ASTH has been the topic of several recent analyst reports. Robert W. Baird cut their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a report on Monday. Bank of America lowered their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Truist Financial dropped their price objective on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Finally, Stifel Nicolaus cut their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th.

Astrana Health Price Performance

Shares of Astrana Health stock opened at $27.21 on Friday. The business’s fifty day moving average price is $34.44 and its 200 day moving average price is $44.05. The stock has a market capitalization of $1.53 billion, a P/E ratio of 20.93, a PEG ratio of 1.37 and a beta of 1.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a twelve month low of $23.12 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. As a group, research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Trading of Astrana Health

A number of large investors have recently made changes to their positions in ASTH. Janus Henderson Group PLC acquired a new position in Astrana Health during the 3rd quarter worth approximately $1,164,000. Royce & Associates LP acquired a new position in Astrana Health during the third quarter worth $6,661,000. Amalgamated Bank acquired a new stake in Astrana Health in the 3rd quarter valued at $713,000. Principal Financial Group Inc. acquired a new stake in Astrana Health in the 3rd quarter valued at $13,383,000. Finally, Loomis Sayles & Co. L P acquired a new position in shares of Astrana Health during the 3rd quarter worth about $30,251,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.